ESG is still undermining fiduciary duty April 2, 2026 Donald Trump may have forced many banks and asset managers to drop the term ESG, but trendy diversity and net zero requirements are still very much alive, and they’re undermining your property rights, says James Graham For some years, the term ‘ESG’ (Environment, Social, and Governance) dominated the world of finance, a shorthand for trendy [...]
Broadgate Central: accessible design pioneers a more inclusive city. April 1, 2026 The City of London has long been a place where people, culture and commerce meet. As the Square Mile continues to develop, our focus is increasingly to ensure the City remains a global centre of business, but also a genuinely welcoming, accessible and enjoyable place for everyone who spends time here. At Broadgate Central, right [...]
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 April 1, 2026 Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the [...]
Steele Raymond Expands Central South Footprint With Williams Thompson Acquisition, Continuing Ambitious, Demand-led Growth Strategy April 1, 2026 Steele Raymond has acquired Williams Thompson, the long-established Christchurch, Dorset law firm, strengthening Steele Raymond’s presence across the region and expanding the specialist support available to clients in Christchurch and the surrounding area. Williams Thompson has a respected local reputation for family, residential property and private client work. Its lawyers will join Steele Raymond’s existing [...]
Forget ‘price gouging’ – this is where competition is really failing April 1, 2026 Rachel Reeves is scapegoating supermarkets for rising oil prices while ignoring algorithms that can learn ant-competitive pricing strategies, says Paul Ormerod The government is desperately trying to convince the public that it is doing something about the potential economic crisis which is unfolding. The public finances are a severe constraint on its ability to throw [...]
Gen Z still wants ESG April 1, 2026 There's still a case for purpose over profit, not least because our Gen Z business successors are demanding it, writes Natasha Frangos.
Andy Haldane: My mission to ignite Britain’s animal spirits March 31, 2026 As the Bank of England’s chief economist, Andy Haldane had a front row seat to the maladies of UK’s sluggish economy. After a four-year stint running the RSA, he is back as president of the British Chambers of Commerce, and tells Ali Lyon business is still taxed mindlessly, over regulated, and far too risk averse. [...]
Britain is still paying a heavy price for Covid lockdowns March 31, 2026 Six years on from the first lockdown, Britain hasn’t returned to its pre-Covid path – instead becoming a high-tax, low-growth less free nation, says Alex Pugh A little over six years ago, 27m people watched UK Prime Minister Boris Johnson tell them to “stay home” to tackle the spread of coronavirus. Johnson said you should [...]
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote March 30, 2026 Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased. Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks. Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority.
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy March 30, 2026 Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen.